Although respiratory syncytial virus (RSV) was discovered> 40 years ago, treatment remains
largely supportive. There are no safe and effective vaccines or specific treatments other than …

Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract
infections in infants and young children, accounting for more than 100,000 hospitalizations …

Respiratory syncytial virus (RSV) remains a significant cause of morbidity and mortality in
infants, immunocompromised patients and the elderly. Despite the high disease burden, an …

Introduction: Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract
infections (LRTI) in infants, the elderly, and the immunocompromised. Although the …

Two meetings, one sponsored by the Wellcome Trust in 2012 and the other by the Global
Virology Foundation in 2013, assembled academic, public health and pharmaceutical …

Introduction Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory
tract disease in young children and a substantial contributor to respiratory tract disease …

Introduction Human respiratory syncytial virus (hRSV) is the primary viral cause of
respiratory diseases, leading to bronchiolitis and pneumonia in vulnerable populations. The …

Respiratory syncytial virus (RSV) is a major cause of respiratory tract infections in infants,
young children, and older or immunocompromised adults. Although aerosolized ribavirin …

Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract
infection (LRTI) in children, causing approximately 3.6 million hospitalizations per year, and …

Since the discovery of the human respiratory syncytial virus (hRSV), multiple research efforts
have been conducted to develop vaccines and treatments capable of reducing the risk of …